The NJBIZ Best Places to Work program evaluates organizations based on rigorous criteria including workplace policies, demographic data, and confidential employee feedback that gauges leadership effectiveness, internal communication, engagement levels, and overall workplace satisfaction. Kessler Foundation’s consistent recognition underscores its dedication to cultivating a culture where professional growth, collaboration, and innovation are prioritized.

At the core of Kessler Foundation’s mission is pioneering rehabilitation research targeting neurological and developmental disabilities such as traumatic brain injury, spinal cord injury, stroke, multiple sclerosis, and autism. The foundation’s scientists are developing and testing novel interventions to enhance mobility, cognitive function, employment outcomes, and quality of life. Their work is supported through a combination of federal and state research grants, private philanthropy, and collaborative partnerships with various nonprofits.

Rodger DeRose, president and CEO, emphasized the critical role of employees in driving the foundation’s success. “Our team’s talent, dedication, and generosity fuel our mission. By fostering an inclusive, purpose-driven environment, we enable innovation that creates meaningful change for people with disabilities,” he stated. This employee-centric approach not only advances scientific discovery but also strengthens the community impact of Kessler Foundation’s programs.

Kessler Foundation’s research integrates cutting-edge technology and evidence-based methodologies to develop interventions tailored to individual needs. By analyzing data on community participation and workforce inclusion, the foundation addresses systemic barriers to employment for people with disabilities, aiming to construct a more accessible and equitable society.

Their workforce benefits from a supportive culture that encourages leadership development, open communication, and shared achievement. The repeated Best Places to Work awards reflect a stable organizational climate where engagement and employee well-being are paramount.

Looking ahead, NJBIZ will reveal the official rankings of this year’s honored employers at an upcoming ceremony, celebrating those who set new standards for workplace excellence in New Jersey.

Through innovative rehabilitation science and a steadfast commitment to its people, Kessler Foundation continues to redefine the possibilities for recovery and independence among individuals with disabilities, setting an inspiring example in both research and workplace culture.

Subject of Research: Rehabilitation research focused on neurological and developmental disabilities including traumatic brain injury, spinal cord injury, stroke, multiple sclerosis, and autism.

Article Title: Kessler Foundation Earns NJBIZ Best Places to Work Recognition for 2026

News Publication Date: July 9, 2026

Web References: https://kesslerfoundation.org/

Image Credits: NJBIZ

Keywords: Rehabilitation research, workplace culture, employee engagement, traumatic brain injury, spinal cord injury, stroke, multiple sclerosis, autism, NJBIZ Best Places to Work

NAI senior membership is a prestigious acknowledgment awarded to academic inventors whose technological creations have exhibited significant potential to impact society profoundly. It emphasizes accomplishments in patenting, licensing, and commercializing technologies that bridge scientific ingenuity with societal needs. These scholars’ inclusion underscores not only their individual achievements but also the collaborative spirit of the broader scientific community that underpins these advancements. The 2026 NAI annual conference, to be hosted by USC at the Loews Hollywood Hotel, will officially recognize these innovators, symbolizing the institution’s role as a global hub for academic innovation.

Paula Cannon, a distinguished professor at USC, has forged a pioneering path in gene therapy and cell-based treatment development, particularly targeting HIV/AIDS and various other diseases. Her laboratory’s innovations in gene editing and therapeutic delivery techniques have become foundational to clinical trials, exemplified by a recent HIV/AIDS trial backed by the California Institute for Regenerative Medicine and industry partners. Her current research revolves around engineering B cells—immune cells responsible for antibody production—to function as targeted therapeutic antibody factories, extending the paradigm established by CAR T-cell therapies. This approach harnesses the body’s immune arsenal in novel ways, potentially revolutionizing treatments for infectious diseases, cancer, and autoimmune conditions.

Cannon emphasizes the pragmatic development cycle of her work, acknowledging the extended trajectory from invention to clinical impact. Her efforts exemplify the integration of academic research with patentable technologies that can be licensed and further developed by industry. Central to this progress is USC’s comprehensive innovation infrastructure, including the Stevens Center for Innovation and the MESH Academy, which facilitate the transition of foundational science into viable therapeutics and foster interdisciplinary collaboration. Cannon’s vision illustrates a model where intricate scientific discovery synergizes with meticulous translational pathways.

Alan Epstein’s career spans nearly four decades of innovative work in monoclonal antibodies and other cancer-fighting technologies. His expertise lies in the development of custom-designed antibodies that have become staples in treating cancers and autoimmune diseases. Epstein is currently focused on a cutting-edge project enhancing antibody therapies by conjugating them with bacterial DNA fragments that can potentiate immune cell activation. Such molecular complementation seeks to enhance the immune system’s innate ability to target malignancies more effectively, marking a significant conceptual progression built upon longstanding fundamental research.

Epstein’s scientific journey underscores the increasing necessity for collaborative networks in biomedical innovation. Throughout his career, he has leveraged partnerships across pathology, radiology, and pharmaceutical sciences at USC, embodying a multidisciplinary approach essential to modern biomedical breakthroughs. He also acknowledges the essential role of committed research personnel who embody resilience and technical acumen in translating complex scientific ideas into practical solutions. Epstein’s reflections highlight the evolving landscape of scientific research where collaboration multiplies impact and accelerates discovery.

Heinz-Josef Lenz, a University Professor of Medicine and Cancer Biology, delves deep into the molecular characterization of colorectal cancer. His research seeks to decode the molecular signatures that define tumor behavior, enabling predictive diagnostics, targeted therapeutics, and personalized treatment regimens. By integrating advanced analytical tools including artificial intelligence with clinical tissue profiling, Lenz identifies previously underexplored biochemical pathways that can serve as therapeutic targets. His work exemplifies the fusion of computational biology with experimental oncology to inform next-generation cancer therapies and precision medicine.

Lenz’s strategy of moving fluidly between clinical observations and laboratory investigations exemplifies the bidirectional flow of knowledge essential for translating scientific insights into patient benefit. His collaborative partnerships extend beyond the biomedical sciences to include engineering and data science faculties at USC, creating a multidisciplinary nexus that leverages diverse expertise. Joint projects, such as novel drug combinations that augment the efficacy of standard chemotherapy with targeted molecular inhibitors, illustrate the practical outcome of this synergy, positioning USC at the forefront of innovating cancer treatment modalities.

Bodour Salhia’s research focuses on the development of liquid biopsies for cancer detection, a transformative diagnostic approach that captures circulating tumor DNA from blood samples. This non-invasive technique promises earlier diagnosis, more accurate disease monitoring, and reduced dependency on invasive tissue biopsies. Salhia’s unique contribution lies in her focus on epigenetic markers—chemical modifications that regulate gene activity without changing the DNA sequence—as opposed to purely genetic mutations. This nuanced approach enhances the sensitivity and specificity of cancer detection assays, especially for ovarian and breast cancers.

Salhia’s entrepreneurial spirit complements her scientific endeavors. She founded CpG Diagnostics, a startup dedicated to commercializing blood-based cancer diagnostics derived from her patented epigenetic technology. These tests aim to detect residual disease post-treatment and differentiate benign from malignant tumors, filling significant clinical gaps. Additionally, her engagement with patient communities via the Bench with Bedside Initiative promotes research transparency and participant involvement, fostering a reciprocal relationship that drives clinical research and patient hope alike.

These four academics embody the transformative power of university-driven innovation ecosystems, where cutting-edge research, entrepreneurial ventures, and cross-disciplinary collaboration converge to address some of humanity’s most daunting health challenges. Their work demonstrates key principles in modern biomedical innovation: driving inventions from concept through patenting and licensing, harnessing the immune system in novel ways, leveraging molecular and computational biology for precision medicine, and applying epigenetic insights to revolutionize diagnostics. As senior members of the NAI, they exemplify how sustained academic endeavor spurs real-world impact, underscoring USC’s commitment to shaping the future of health care technologies.

As the 2026 NAI conference approaches, the Keck School of Medicine’s spotlighted innovators stand as exemplars of the potent blend of scientific creativity, clinical insight, and entrepreneurial rigor essential for advancing human health. Their stories resonate broadly not only within academic and medical circles but also across industries and patient communities eager for breakthroughs. Through steadfast dedication and collaborative spirit, these four leaders continue to propel the boundaries of medicine, translating visionary science into tangible hope.

Subject of Research: Gene and cell therapies, monoclonal antibodies, colorectal cancer molecular profiling, and liquid biopsy diagnostics for cancer detection.

Article Title: USC Innovators Named Senior Members of the National Academy of Inventors for Pioneering Advances in Cancer and HIV Therapies

News Publication Date: Not explicitly stated; inferred 2024

Web References:
– Keck School of Medicine of USC: https://keck.usc.edu
– National Academy of Inventors: https://www.academyofinventors.org
– CpG Diagnostics: https://www.cpgdiagnostics.com
– Bench with Bedside Initiative: https://thebenchwithbedsideinitiative.usc.edu

Image Credits: Don Milici

Keywords: Gene therapy, cell therapy, HIV/AIDS, monoclonal antibodies, cancer diagnostics, colorectal cancer, liquid biopsy, epigenetics, biomedical innovation, academic inventors, USC, National Academy of Inventors

At the helm of this ambitious project are Yimo Han and Chong Xie from Rice, alongside Dr. Damiano Barone from Houston Methodist. Their collective aim is to improve the understanding of the intricate dynamics between implanted neural devices and brain tissue. Through this research, the team seeks to create neural implants that are not just functional but also harmoniously integrated with the brain, potentially revolutionizing treatment options for neurological disorders like Parkinson’s disease and epilepsy.

One of the critical focal points of the research is the study of nanoelectronic threads (NETs)—ultraflexible electrodes capable of recording brain activity while simultaneously delivering neurostimulation with minimal adverse impact on surrounding tissues. This ultra-flexible design promises to mitigate the chronic inflammation and tissue scarring often associated with traditional brain implants, thereby improving overall device longevity and performance.

Utilizing advanced visualization techniques, Han’s group will explore the interface between the NETs and adjacent brain cells, gaining insights into how the human tissue envelops these foreign objects. The analysis will delve deeply into the cellular architecture at a nanometer resolution. Through this examination, the researchers hope to determine the physiological conditions that favor stable, long-term integration of these devices within the brain.

Barone’s contribution to the project focuses on mapping cellular responses at a genetic level, examining how individual brain cells react to the presence of NETs. This detailed genetic mapping will elucidate the cellular dynamics and immune responses provoked by the implants, establishing a quantitative framework essential for comprehending neuroinflammation processes associated with implanted devices.

The outcomes of this research endeavor are anticipated to have a profound impact on the design and functionality of next-generation neural implants. By enhancing the compatibility of these devices with brain tissue, the team envisions improving the reliability and effectiveness of treatments for patients suffering from debilitating neurological conditions, thereby transforming patient care and outcomes.

As the project evolves, Barone emphasized the importance of understanding the immune and fibrotic responses triggered by implanted devices. This knowledge is vital for devising strategies that predict and control biological reactions to the implants, ultimately leading to more predictable patient outcomes. The interdisciplinary collaboration between researchers adept in various fields will foster a systematic analysis of these complex biological processes, setting a precedent for integrative approaches in biomedical research.

Xie, who leads the lab responsible for the development of NETs, has previously witnessed these probes’ promising performance in animal models. His team’s innovative designs aim to overcome the challenges typically encountered by conventional brain implants. By meticulously studying the biological mechanisms at play, they hope to unveil the specific factors that contribute to the stability and longevity of ultraflexible probes, ultimately resulting in superior patient outcomes.

The John S. Dunn Foundation Collaborative Research Award Program serves as a catalyst for fostering interdisciplinary and interinstitutional research in the quantitative biomedical sciences. By focusing on early-stage collaborations among varied investigators from multiple institutions, the program has the potential to ignite significant advancements in the field, addressing critical challenges in biomedical science.

Projects funded through this program are meticulously evaluated based on scientific quality, novelty, and potential for long-term impact on human health. The ongoing collaboration between the Rice University team and the Houston Methodist Research Institute embodies the spirit of innovation and progress that the Dunn Foundation aims to advance.

The research team expressed gratitude for the unique framework provided by the Dunn Foundation and the Gulf Coast Consortia, allowing them to embark on this project. They are eager to contribute essential preliminary data to the burgeoning field of neural implants, establishing a foundation for future discoveries and developments.

With a shared vision of enhancing the quality of life for individuals suffering from neurological disorders, this collaboration could pave the way for a new era of brain-computer interfaces and neuroprostheses that are not only effective but also seamlessly integrated with the body’s own tissue. The pursuit of this research serves as a testament to the potential of interdisciplinary collaboration to address complex scientific questions and ultimately improve human health.

The implications of this research extend far beyond basic scientific inquiry; it represents a clarion call for collaboration across disciplines to tackle some of the most pressing challenges in medical technology today. As the understanding of brain-tissue integration progresses, the dream of creating neural implants that truly mimic the body’s capabilities becomes ever closer to reality. This endeavor exemplifies hope for patients facing severe neurological conditions and provides a path toward more reliable and effective treatments in the near future.

As the findings from this research begin to unfold, the scientific community and healthcare professionals remain keenly interested in the advancements that these researchers will unveil. The study of how the brain interacts with implanted devices is poised to spark new conversations and inspire further exploration, driving innovation in the fields of neuroscience and biomedical engineering for years to come.

In the grand tapestry of scientific research, this collaborative effort shines brightly, highlighting the importance of interdisciplinary synergy in creating innovative solutions for human health challenges. As the team embarks on this transformative journey, it stands as a beacon of hope for all those affected by neurological disorders, with the promise of a future where brain-computer interfaces elevate quality of life and redefine the possibilities of medical technology.

Subject of Research: Brain response to neural implants
Article Title: Investigating the Brain’s Adaptation to Neural Implants
News Publication Date: November 6, 2025
Web References: https://news.rice.edu/
References: [Not Applicable]
Image Credits: Credit: Photo by Jorge Vidal/Rice University.

Keywords

• Neuroscience
• Neural prosthetics
• Brain stimulation
• Neuroinflammation
• Neurodegenerative diseases
• Clinical neuroscience
• Brain-tissue integration
• Materials science
• Biomedical engineering
• Immune response
• Inflammation
• Neurophysiology

The fundamental challenge of creating an artificial heart lies in its need to mimic the functionality of a biological heart, which tirelessly works for decades without fail. According to Tino Ebbers, a professor of physiology at Linköping University, achieving this level of reliability in a mechanical pump is an immense engineering challenge. In the quest for developing such a device, understanding the dynamics of blood flow becomes essential. The research team tackled this issue by modeling the human circulatory system at a full scale, enabling them to visually capture and analyze blood flow patterns using advanced imaging techniques.

In recent years, the global demand for heart transplants has escalated, with nearly 9,000 operations carried out worldwide annually. Despite these efforts, the waitlist for viable donor hearts continues to grow, affecting thousands of patients who find themselves tethered to mechanical pumps to sustain their blood circulation. For these individuals, an artificial heart could provide a critical lifeline while they await a transplant, allowing them a greater quality of life and the ability to spend time with loved ones instead of being confined to a hospital bed.

The researchers emphasize the critical role of continuous blood flow within an artificial heart to prevent potential complications. High velocities and turbulence can lead to hemolysis, the destruction of red blood cells, while stagnation can create ideal conditions for clot formation. The team’s groundbreaking use of MRI technology allows them to observe these dynamics in real time, fundamentally changing how artificial hearts will be optimized in the future.

Tino Ebbers highlighted the uniqueness of this imaging technology, stating that it enables scientists to visualize the conditions inside a heart without the need for invasive procedures. This non-invasive observation can revolutionize research and development in the field, yielding insights that translate directly into better-designed devices. The researchers’ analysis indicated that the blood flow patterns observed in the prototype closely resembled those found in a healthy human heart, validating their design.

The artificial heart developed by Scandinavian Real Heart recently earned the Humanitarian Use Device (HUD) designation from the US Food and Drug Administration (FDA). This status provides a pathway for the device to move through an accelerated regulatory process, potentially leading to its limited marketing and clinical application in a few years. The researchers acknowledge that while they are making strides, extensive pre-clinical and clinical studies are still necessary before the technology can be implemented in patient care.

The vision driving this research is to create an artificial heart that serves as a permanent solution rather than a temporary aid. The clinical goal is to establish the device as a bridge to transplantation, offering a reliable mechanism to keep patients alive while they await a heart from a donor. The prospect of such a device speaks to heart disease management and the future of transplantation, where reliance on human donors could be alleviated.

Patients currently reliant on mechanical support for circulation often experience a diminished quality of life. The artificial heart, if successful, could enable mobility and interaction for patients while avoiding waits in sterile hospital environments. As Ebbers articulated, bridging the gap between these patients and potential transplants could ultimately enhance their lives.

The research team at Linköping University is committed to refining this technology to address the complexities associated with artificial circulatory systems. As the interplay between speed and stagnation is adjusted in future prototypes, they aim to create more efficient designs that promote healthy blood flow and minimize complications, thereby enhancing device viability and longevity.

The advancements represented by this research illuminate a future where lives can be sustained through advanced medical devices that emulate biological systems with remarkable fidelity. By incorporating innovative imaging techniques such as real-time MRI, researchers are embarking on a transformative journey that could redefine hearts, longevity, and the very nature of organ replacement therapy.

As the technology advances, the implications stretch beyond mere functionality—they extend to ethical considerations regarding organ transplants, patient autonomy, and medical innovation in the face of an ever-growing demand for viable heart solutions.

While navigating these uncharted waters, the collaboration with Scandinavian Real Heart AB is expected to yield a wealth of clinical data and insights. The researchers remain hopeful that the artificial heart will smoothly transition from the laboratory to the clinic, heralding a new era in cardiac care that prioritizes patient well-being and quality of life.

Given the prevalence of heart conditions globally, the potential for this advanced technology to serve as a reliable heart replacement could reshape medical paradigms. The next few years will be critical in determining the success of this research and its journey toward practical application, but the momentum generated thus far is encouraging and offers hope to those waiting for heart transplants.

With the ongoing pursuit of innovation in artificial heart design, researchers and medical professionals alike are determined to pave the way for a future where dependence on donor hearts is significantly reduced, potentially revolutionizing cardiac care for generations to come.

Subject of Research: Not applicable
Article Title: 4D flow MRI enhances prototype testing of a total artificial heart
News Publication Date: 15-Sep-2025
Web References: 10.1038/s41598-025-18422-y
References: Not applicable
Image Credits: Credit: Emma Busk Winquist

Keywords

Artificial heart, blood flow, MRI, Scandinavian Real Heart, heart transplant, hemolysis, cardiac care, Tino Ebbers, Linköping University, non-invasive imaging, medical innovation, Technology, medical devices.

The trial, which has secured $16 million in funding from the Patient-Centered Outcomes Research Institute (PCORI), represents the first large-scale randomized effort in the U.S. to systematically investigate how AI can support radiologists in interpreting mammograms. By leveraging advanced AI algorithms integrated through clinical workflows, this study aims to enhance early cancer detection, simultaneously reducing false positive rates and unnecessary patient recalls—problems that frequently plague conventional mammography screening programs, leading to patient anxiety and increased healthcare costs.

PRISM involves a collaborative network spanning seven leading academic institutions across six states—including UCLA, UC Davis, Boston Medical Center, UC San Diego, Sylvester Comprehensive Cancer Center, University of Washington-Fred Hutchinson Cancer Center, and University of Wisconsin-Madison. These centers will interpret hundreds of thousands of mammograms using a randomized approach where images are either assessed by radiologists unaided or with the decision support of an FDA-cleared AI platform known as Transpara by ScreenPoint Medical, seamlessly integrated into clinical workflows via the Aidoc aiOS platform.

The AI system in question operates by analyzing mammographic images using deep convolutional neural networks optimized for breast tissue characterization. This technology quantifies risk scores indicating the likelihood of malignancy, thereby providing radiologists with an AI-derived second opinion. Importantly, despite the assistance offered by AI, participating radiologists retain full control over final diagnostic decisions, ensuring clinical expertise remains paramount.

Jose Net, M.D., Director of Breast Imaging Services at Sylvester and co-principal investigator of the trial, emphasizes the critical balance sought in this research. “Our objective is not to replace the radiologist but to understand precisely how AI tools can augment diagnostic accuracy in a meaningful and patient-centered way,” Dr. Net remarks. The trial’s patient-first design reflects this ethos by maintaining existing screening protocols at each center, without any alteration in the patient experience or additional procedural burden.

The scientific premise for this trial arises from the challenges associated with mammographic screening. While mammography remains the cornerstone for early breast cancer detection and has demonstrably reduced mortality rates, limitations such as false positives—which generate unnecessary follow-up tests and psychological distress—and false negatives, where cancers go undetected, necessitate improvements in interpretation methodologies. AI holds transformative potential, but its actual performance in clinical environments has remained under-explored until now.

With regard to study design, mammograms will be randomized upon acquisition, ensuring that some images are read with AI assistance and others are interpreted solely by radiologists in the standard of care arm. This randomization enables robust comparative effectiveness evaluation, allowing researchers to quantify the impact of AI integration on cancer detection rates, recall rates, and diagnostic workflow efficiency. The pragmatic, real-world nature of the trial further ensures that findings will be directly translatable into clinical practice.

Complementing the quantitative analyses, the PRISM Trial incorporates qualitative components such as focus groups and surveys targeting both patients and radiologists. These instruments aim to capture perceptions, trust levels, and acceptance of AI in diagnostic decision-making, addressing an often-overlooked dimension in AI deployment: user and patient engagement and confidence in technology-augmented care pathways.

This trial stands as possibly the most ambitious effort yet to generate high-quality evidence on AI’s role in breast cancer screening. It is expected to inform not only clinical protocols but also insurance reimbursement policies and technology adoption strategies, as the healthcare industry grapples with integrating AI into routine care while safeguarding patient safety and optimizing outcomes.

Another pivotal aspect of PRISM is its extensive geographic and institutional reach, encompassing diverse populations and healthcare settings. This inclusivity ensures that the study evaluates AI performance across varied demographic cohorts and facility types, thereby increasing the generalizability of its conclusions and helping to identify subgroups who may derive particular benefit—or conversely, where AI assistance may not add value.

The underlying technical infrastructure supporting the trial is robust, featuring state-of-the-art AI models trained on large-scale imaging datasets and continuously updated through machine learning techniques to refine predictive accuracy. These systems operate within secure computational environments that comply with healthcare data privacy regulations, ensuring patient information confidentiality throughout the study.

The outcome of this pioneering research initiative will ultimately shed light on whether AI can reliably augment radiologists’ interpretative accuracy, reduce unnecessary recalls, and alleviate patient anxiety without compromising diagnostic safety. As Dr. Net notes, “We are poised to generate the evidence necessary to integrate AI thoughtfully, preserving the indispensable role of human expertise while harnessing the power of computational advances.”

Readouts from the PRISM Trial will offer vital guidance to clinicians, hospital administrators, policymakers, and payers as the healthcare system navigates the complex challenges and opportunities presented by AI. This trial not only pushes the boundaries of medical imaging technology but also embodies a patient-centered approach to innovation, prioritizing trust, transparency, and real-world applicability.

For ongoing updates on this and other related advancements, the Sylvester Comprehensive Cancer Center maintains a dedicated presence on their InventUM blog and social media channels, fostering open dialogue and dissemination of new knowledge to the broader scientific community and the public.

Subject of Research: Artificial intelligence in breast cancer screening and mammography interpretation

Article Title: (Not specified in the provided content)

News Publication Date: September 23, 2025

Web References:

• Sylvester Comprehensive Cancer Center: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center
• InventUM blog on AI and breast cancer screening: https://news.med.miami.edu/studying-artificial-intelligence-in-breast-cancer-screening/
• Sylvester Cancer on X (formerly Twitter): https://x.com/SylvesterCancer

Image Credits: Photo by Sylvester Comprehensive Cancer Center

Keywords: Mammography, Diagnostic imaging, Breast cancer, Medical technology, Radiology

Traditional health AI systems have largely been designed within rigid binary gender models, frequently neglecting the unique physiological and psychosocial needs of transgender and non-binary populations. Such limitations not only restrict the utility of AI-powered healthcare tools for these communities but also risk exacerbating existing health disparities. The recent study delves into these concerns by engaging members of the transgender community directly in its research process, embracing a communicative methodology that emphasizes participatory collaboration rather than top-down analysis. This approach marks an essential shift in biomedical AI research, highlighting the importance of involving marginalized groups to co-create more equitable technologies.

The research was conducted in close partnership with the LGBTQIA+ advocacy group PRISMA, which plays a pivotal role in defending the rights of sexual and gender minorities within scientific and technological innovation spheres. This collaboration ensured that the study remained grounded in real-world experiences and ethical imperatives, avoiding the common pitfall of tokenistic inclusion. Representatives from the Health Care and Promotion Service for Trans and Non-Binary People (TRÀNSIT) at the Catalan Health Institute also provided critical insights, further enriching the study’s contextual relevance and fostering trust between researchers and participants.

At the heart of the study were three telematic focus groups composed of eighteen transgender individuals tasked with articulating their experiences and perspectives concerning current AI applications in healthcare. Participants reported that many existing AI tools propagate the biases of their predominantly cisgender developers. As an illustrative example, certain voice modification applications, designed to assist in gender transition, frequently misclassify users by gender. This misrecognition not only undermines the app’s therapeutic efficacy but also inflicts emotional distress on users by invalidating their gender identity through technology.

Such technological missteps are emblematic of a larger problem: the replication and amplification of societal biases within AI systems. This pernicious feedback loop leads to the invisibilization of transgender people, reinforcing structural inequities. Simón Perera del Rosario, a co-author from UPF, highlighted that this dynamic can have deleterious effects on mental health, self-esteem, and overall quality of life for transgender individuals. These findings emphasize the ethical imperative to design AI systems that are not just functionally effective but also socially responsible.

One of the study’s major recommendations focuses on leveraging AI’s capabilities to enhance the personalization of medical treatments, notably in the administration of masculinizing or feminizing hormonal therapies. Currently, hormone dosages are often standardized according to cisgender parameters, ignoring the distinct physiological profiles within transgender populations. AI systems, equipped with diverse data reflecting individual variations, could optimize dosage regimens and monitor potential interactions with other medications, thus minimizing side effects and maximizing therapeutic outcomes. This precision medicine approach marks a significant advance toward truly individualized care.

Participants also stressed the crucial importance of ethical data management. Their concerns revolve around how personal data related to gender identity is collected, stored, and used within medical systems. The group advocated for strictly limiting the use of such sensitive data to relevant medical contexts, entrusting only qualified health professionals with this information. This precaution is vital to prevent unauthorized misuse and to respect privacy, which has historically been a major barrier for transgender individuals seeking care. Furthermore, participants warned that AI systems built on binary frameworks risk misinterpreting data, thereby leading to diagnostic inaccuracies or inappropriate treatment decisions.

The mistrust of healthcare institutions among many transgender individuals is a significant hurdle that technology alone cannot overcome. This distrust stems from a long history of discrimination and medical pathologization, underscored by the World Health Organization’s delayed removal of “transsexuality” as a mental disorder only in 2019. To rebuild trust, the study underscores the necessity for comprehensive healthcare professional education and sensitization to transgender-specific health needs. Such training initiatives would enhance provider competence and foster more respectful, informed patient interactions, which are essential for effective AI integration in clinical practice.

Expanding the scientific evidence base concerning transgender health and AI is another vital pillar of the study’s agenda. Current research addressing these intersecting domains remains alarmingly sparse. There is an urgent need for more scholarly attention focused on developing AI models that reflect gender diversity holistically, from data collection to algorithmic design and deployment. Encouraging interdisciplinary collaboration among computer scientists, clinicians, and social scientists will be critical to ensuring these models are robust, ethical, and clinically impactful.

Moreover, fostering solidarity networks and knowledge exchange platforms between transgender communities and healthcare professionals holds great promise. These spaces enable the co-creation of AI tools grounded in lived experience, thereby enhancing relevance and acceptance. By engaging stakeholders throughout AI development cycles, the healthcare field can produce technologies that empower rather than alienate marginalized groups.

The study’s communication methodology itself represents an innovative research paradigm that upends conventional investigator-led approaches. By actively involving transgender participants in the research design and oversight, facilitated by PRISMA, the research ensured that ethical standards were meticulously upheld and that outcomes would resonate authentically with the community. This participatory ethic exemplifies a progressive direction for AI research writ large, emphasizing inclusivity, transparency, and reciprocal respect.

In conclusion, the ongoing evolution of AI in healthcare offers unprecedented opportunities to deliver personalized, equitable medical care. However, realizing this potential necessitates deliberate efforts to dismantle ingrained binary biases in AI systems. The interdisciplinary collaboration between UPF, BSC-CNS, URV, and advocacy partners like PRISMA points the way toward constructing AI applications that truly reflect and serve the diverse tapestry of human gender identities. Embracing this vision promises not only to improve health outcomes for transgender individuals but also to enrich the field of AI-powered medicine as a whole with more nuanced, just, and humane technologies.

Subject of Research: People

Article Title: Exploring Gender Bias in AI for Personalized Medicine: Focus Group Study With Trans Community Members

News Publication Date: 29-Jul-2025

Web References:

• Journal of Medical Internet Research DOI link
• PRISMA association
• TRÀNSIT Health Care and Promotion Service

References: None declared.

Keywords:
Artificial intelligence, Personalized medicine, Algorithms, Transgender identity

Pediatric heart transplantation is an intricate and highly specialized medical procedure that plays a critical role in the survival of children with end-stage heart disease. Unlike adult transplantations, pediatric cases present unique challenges including limited donor availability, the physiological nuances of growing bodies, and the complex immunological responses in children. These factors necessitate continuous innovation and collaborative efforts in scientific research, clinical practice, and healthcare policy to improve both procedural success and long-term patient outcomes.

The newly formed Pediatric Heart Transplant Alliance envisions a future where interdisciplinary collaboration serves as the bedrock for transforming pediatric transplant care. By uniting nonprofit organizations, academic researchers, clinicians, industry leaders, and advocacy groups, the Alliance aims to harness collective expertise and resources. This approach is fundamental to overcoming barriers such as donor organ scarcity, graft rejection, and complications arising from immunosuppression in pediatric patients, which have historically limited transplant success.

One of the core objectives of the PHTA is to propel cutting-edge research focused on enhancing transplant survival rates and quality of life for pediatric recipients. This includes exploring novel immunomodulatory therapies to fine-tune immune tolerance, advancing biomarker discovery to predict rejection episodes early, and refining surgical techniques tailored to pediatric anatomies. Additionally, the Alliance supports integrating emerging technologies such as bioengineering and regenerative medicine, which hold promise for creating bioartificial hearts and minimizing reliance on donor organs.

Education forms another cornerstone of the Alliance’s efforts. The complexity of managing pediatric heart transplant requires comprehensive training that spans not only medical professionals but also caregivers and families. PHTA is dedicated to generating robust educational resources that cover pre-transplant evaluations, perioperative care, long-term monitoring, and psychosocial support. By empowering stakeholders with deeper understanding, the Alliance aims to enhance patient adherence, identify complications promptly, and improve overall transplant success.

Increasing access to care remains a pressing concern in pediatric heart transplantation. Geographic disparities, economic barriers, and limited specialized centers impede timely treatment for many children. The Pediatric Heart Transplant Alliance is committed to addressing these inequities by advocating for policy reforms, expanding donor organ utilization efficiency, and fostering telemedicine initiatives. These endeavors seek to democratize access and ensure all pediatric patients receive the highest standard of care regardless of location or socioeconomic status.

This year marks a significant milestone as the medical community commemorates the 10,000th pediatric heart transplant performed worldwide. This landmark achievement underscores the profound impact transplantation has had on improving survival and quality of life for children with life-threatening cardiac conditions. Despite these advances, leading experts emphasize that continuous innovation and multidisciplinary collaboration are vital to move past existing limitations and pioneer new frontiers in the field.

Lynda Lee Smith, CEO of Enduring Hearts, aptly summarizes this sentiment: “While we celebrate monumental progress in pediatric heart transplantation, we must remain vigilant and driven. The challenges are complex—from understanding the unique immunological landscape in children to addressing long-term outcomes—but with a united alliance, the potential to significantly improve survival and life quality is immense.”

Greg Schultz, CEO of ISHLT, highlights the organizational commitment to this cause: “For over four decades, ISHLT has been instrumental in fostering advancements in heart and lung transplantation. Joining forces within the Pediatric Heart Transplant Alliance reinforces our dedication to ensuring every child in need gains access to innovative, compassionate care backed by rigorous scientific research.”

Underlying the Alliance’s mission is a commitment to fostering groundbreaking research initiatives that involve data sharing across institutions, multicenter clinical trials, and investment in novel therapeutic modalities. By leveraging large-scale registries and applying machine learning algorithms, the Alliance hopes to unlock new insights into transplantation outcomes and tailor treatments to individual patient profiles.

Moreover, the Alliance recognizes the psychosocial dimensions of pediatric transplantation, integrating family-centered care models that address emotional support, developmental challenges, and quality-of-life considerations. This holistic approach is designed to optimize not just survival but meaningful, thriving lives post-transplantation.

In conclusion, the Pediatric Heart Transplant Alliance embodies a new era of collaborative excellence in pediatric transplant medicine. With shared vision and concerted action across multiple sectors, the Alliance sets the stage for transformative breakthroughs that stand to redefine pediatric heart transplant care globally. As this coalition embarks on its ambitious journey, the future looks promising for countless children and families navigating the complexities of heart transplantation.

Subject of Research: Pediatric Heart Transplantation, Collaborative Research and Clinical Innovation

Article Title: Six Leading Organizations Unite to Launch the Pediatric Heart Transplant Alliance: A New Era in Pediatric Heart Transplant Innovation

News Publication Date: 27 April 2025

Web References:

• https://www.enduringhearts.org
• https://www.ishlt.org/
• https://pediatrichearttransplantsociety.org/
• https://www.additionalventures.org/
• https://www.transplantfamilies.org/
• https://www.actionlearningnetwork.org/

Image Credits: Pediatric Heart Transplant Alliance